X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PFIZER - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PFIZER CADILA HEALTHCARE/
PFIZER
 
P/E (TTM) x 19.1 34.3 55.6% View Chart
P/BV x 4.5 5.1 89.5% View Chart
Dividend Yield % 0.9 0.7 134.2%  

Financials

 CADILA HEALTHCARE   PFIZER
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
PFIZER
Mar-18
CADILA HEALTHCARE/
PFIZER
5-Yr Chart
Click to enlarge
High Rs5582,365 23.6%   
Low Rs3621,625 22.2%   
Sales per share (Unadj.) Rs116.3430.3 27.0%  
Earnings per share (Unadj.) Rs17.978.7 22.7%  
Cash flow per share (Unadj.) Rs23.193.2 24.8%  
Dividends per share (Unadj.) Rs3.5020.00 17.5%  
Dividend yield (eoy) %0.81.0 75.9%  
Book value per share (Unadj.) Rs85.4586.5 14.6%  
Shares outstanding (eoy) m1,023.7445.75 2,237.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.6 85.3%   
Avg P/E ratio x25.725.3 101.5%  
P/CF ratio (eoy) x19.921.4 92.8%  
Price / Book Value ratio x5.43.4 158.2%  
Dividend payout %19.625.4 77.1%   
Avg Mkt Cap Rs m470,66491,271 515.7%   
No. of employees `00011.82.6 449.4%   
Total wages/salary Rs m18,5453,143 590.1%   
Avg. sales/employee Rs Th10,072.77,484.8 134.6%   
Avg. wages/employee Rs Th1,569.11,195.0 131.3%   
Avg. net profit/employee Rs Th1,547.71,369.1 113.0%   
INCOME DATA
Net Sales Rs m119,04919,685 604.8%  
Other income Rs m1,1321,143 99.0%   
Total revenues Rs m120,18120,828 577.0%   
Gross profit Rs m28,4755,003 569.2%  
Depreciation Rs m5,388663 813.3%   
Interest Rs m9114 21,690.5%   
Profit before tax Rs m23,3085,479 425.4%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,878 300.5%   
Profit after tax Rs m18,2923,601 508.0%  
Gross profit margin %23.925.4 94.1%  
Effective tax rate %24.234.3 70.6%   
Net profit margin %15.418.3 84.0%  
BALANCE SHEET DATA
Current assets Rs m82,00524,167 339.3%   
Current liabilities Rs m60,7209,544 636.2%   
Net working cap to sales %17.974.3 24.1%  
Current ratio x1.42.5 53.3%  
Inventory Days Days7355 132.8%  
Debtors Days Days9829 342.5%  
Net fixed assets Rs m83,7039,514 879.8%   
Share capital Rs m1,024458 223.8%   
"Free" reserves Rs m86,42126,375 327.7%   
Net worth Rs m87,44526,832 325.9%   
Long term debt Rs m25,55125 102,204.0%   
Total assets Rs m180,65336,900 489.6%  
Interest coverage x26.61,305.5 2.0%   
Debt to equity ratio x0.30 31,360.7%  
Sales to assets ratio x0.70.5 123.5%   
Return on assets %10.69.8 108.8%  
Return on equity %20.913.4 155.9%  
Return on capital %22.020.4 107.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68322 190,549.1%   
Fx outflow Rs m11,2421,489 755.2%   
Net fx Rs m31,441-1,466 -2,144.2%   
CASH FLOW
From Operations Rs m9,1933,318 277.1%  
From Investments Rs m-9,737-2,383 408.6%  
From Financial Activity Rs m515-1,104 -46.7%  
Net Cashflow Rs m-29-169 17.2%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.3 7.5 110.7%  
FIIs % 5.9 4.9 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 23.7 46.4%  
Shareholders   44,069 85,207 51.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 21, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS